Proactive Investors - Run By Investors For Investors

Tissue Regenix launches new unit as it inks US distribution deal

The changes will see the company focus on the surgical sector where its DermaPure product is gaining traction
surgeons working
The company has seen significant uptake in the orthopaedic trauma and urogynaecology segments

Tissue Regenix Group PLC (LON:TRX) shares popped higher on Monday morning after the firm announced the launch of a new business unit as well as unveiling an exclusive distribution deal for its flagship product.

Around 10.15am, Tissue Regenix shares were up 1.6% at 7.88p. 

The wound care specialist has set up TRX BioSurgery to further promote its DermaPure graft as surgical application following success in this sphere and the growing adoption of the product.

It has seen significant uptake in the orthopaedic trauma and urogynaecology segments.

Natural evolution

“Progressing from traditional wound care clinical settings to surgical applications is a natural evolution for DermaPure, which has proven to be clinically efficient in just a single application,” said said chief executive Steve Couldwell.

The Tissue Regenix boss also announced the formation of a distribution partnership with ARMS Medical.

Multi-year deal

The multi-year agreement gives ARMS exclusive rights to distribute DermaPure to hospitals and surgeons throughout the US for use in urology and gynecology procedures.

The partnership will allow the UK firm’s direct sales force to maintain their focus on soft tissue regeneration in the wound, plastics, orthopaedics and general surgery markets.

“Our partnership with ARMS Medical, who are known for bringing innovation to women's pelvic health solutions, allows us to leverage their strong relationships with key opinion leaders in the urogynaecology space to further access this market, whilst also maintaining commercial focus in our other key areas," Couldwell.

 -- Adds share price --

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use